The ground-breaking prognostic test that can predict the onset of diabetic kidney disease and future kidney function decline in patients with type 2 diabetes.
Diabetic kidney disease is the leading cause of chronic and end-stage kidney disease worldwide¹. Most people with diabetic kidney disease do not have symptoms². Prevention is better than cure – transform clinical outcomes.
11th November 2022 - PromarkerD patent granted in Hong Kong
9th August 2022 - Proteomics International signs binding letter of intent with Sonic Healthcare USA to take PromarkerD into the US market
2nd August 2022 - American doctors give tick to Proteomics kidney test – The West Australian
2nd August 2022 - Clinical Utility Study demonstrates PromarkerD test benefits
“PromarkerD will save lives and healthcare costs” – Dr Richard Lipscombe to American Diabetes Association (ADA) TV